Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
A phase 1/2 trial of Fludarabine, Cyclophosphamide in pancreatic ductal adenocarcinoma, run by Beijing Biotech, now recruiting.
Overview
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma is a phase 1/2 interventional study registered as NCT07627711 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy). Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide, Pancreatic ductal adenocarcinoma.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Shares Fludarabine, Cyclophosphamide.